Showing results (11-20 of 588) with videos related to
Sort By:
Pageof 59
Cancer Discovery|June 5, 2019
Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor EraRyan J SullivanCancer Discovery|April 1, 2022
For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti-PD-1-Resistant MelanomaRyan J SullivanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2018
Forestalling BRAF-Inhibitor Resistance in a Shocking WayRyan J SullivanCurrent Opinion in Oncology|February 5, 2016
The role of mitogen-activated protein targeting in melanoma beyond BRAFV600Ryan J SullivanThe Lancet. Oncology|February 2, 2013
Which drug, and when, for patients with BRAF-mutant melanoma?Sekwon Jang, Michael B AtkinsCancer Treatment and Research|November 26, 2015
Treatment of Melanoma CNS MetastasesSekwon Jang, Michael B AtkinsJournal of the National Cancer Institute|February 4, 2016
Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current PerspectivesMichael B Atkins, James LarkinExpert Review of Anticancer Therapy|April 28, 2022
Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumabMichael Serzan, Michael B AtkinsJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2015
Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic MelanomaGeoffrey T Gibney, Michael B AtkinsCancer Journal (Sudbury, Mass.)|October 7, 2008
Immunotherapy of metastatic renal cell carcinomaDavid F McDermott, Michael B AtkinsPageof 59